US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Atturra Ltd (ATA) 銘柄情報

Atturra Ltd (ATA)

0.425

-0.005

(-1.16%)

終了 6月6日 3:00PM

Atturra Ltd (ATA) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.425

( -1.16% )

買値

0.40

売値

0.45

出来高

28,436

0.42 日の範囲 0.43

0.39 52 週間の範囲 0.88

時価総額

前日終値

0.43

始値

0.42

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 170,815

発行済株式数

367,817,528

配当利回り

PER

185.03

1 株当たり利益 (EPS)

-

歳入

339.92M

純利益

887k

Atturra Limited, together with its subsidiaries, provides advisory and information technology solutions in Australia, New Zealand, Singapore, North America, and Hong Kong. It provides advisory and consulting, business application, data and integration, cloud services, change management, managed cont... Atturra Limited, together with its subsidiaries, provides advisory and information technology solutions in Australia, New Zealand, Singapore, North America, and Hong Kong. It provides advisory and consulting, business application, data and integration, cloud services, change management, managed control solutions, and industry engagement and managed services. The company serves defense, federal and state government, financial services, education, manufacturing, local government, utilities, and resources industries. Atturra Limited was founded in 2015 and is headquartered in Sydney, Australia. 詳細を表示

セクター

Technology

業界

Software & It Services

ウェブサイト

atturra.com

本社

Sydney, Australia

設立

2026

Atturra Ltd is listed in the Technology sector of the オーストラリア証券取引所 with ticker ATA. The last closing price for Atturra was AUD0.43. Over the last year, Atturra shares have traded in a share price range of AUD 0.39 to AUD 0.88.

Atturra currently has 367,817,528 shares in issue. The market capitalisation of Atturra is AUD156.32 million. Atturra has a price to earnings ratio (PE ratio) of 185.03.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.025	-5.55555555556	0.45	0.455	0.39	70997	0.43526402	DE
4	-0.04	-8.60215053763	0.465	0.505	0.39	97292	0.44706175	DE
12	-0.135	-24.1071428571	0.56	0.575	0.39	144111	0.50805328	DE
26	-0.4	-48.4848484848	0.825	0.845	0.39	221521	0.63478512	DE
52	-0.425	-50	0.85	0.88	0.39	202283	0.70699287	DE
156	-0.505	-54.3010752688	0.93	4632.19	0.39	152739	0.80413036	DE
260	-0.065	-13.2653061224	0.49	4632.19	0.39	152168	0.76847278	DE

ATA - Frequently Asked Questions (FAQ)

What is the current Atturra Ltd share price?

The current share price of Atturra Ltd is AUD 0.425

How many Atturra Ltd shares are in issue?

Atturra Ltd has 367,817,528 shares in issue

What is the market cap of Atturra Ltd?

The market capitalisation of Atturra Ltd is AUD 156.32M

What is the 1 year trading range for Atturra Ltd share price?

Atturra Ltd has traded in the range of AUD 0.39 to AUD 0.88 during the past year

What is the PE ratio of Atturra Ltd?

The price to earnings ratio of Atturra Ltd is 185.03

What is the cash to sales ratio of Atturra Ltd?

The cash to sales ratio of Atturra Ltd is 0.47

What is the registered address of Atturra Ltd?

The registered address for Atturra Ltd is 10 Bond Street, Sydney, New South Wales, 2000

What is the Atturra Ltd website address?

The website address for Atturra Ltd is atturra.com

Which industry sector does Atturra Ltd operate in?

Atturra Ltd operates in the Software & IT Services sector

US Market News

US Market News 6分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 6分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 8分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 11分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 12分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 15分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 15分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 15分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 19分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 19分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 20分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 21分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 22分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 23分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 23分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 24分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 24分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 25分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 25分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 26分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 28分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 31分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

Flexshares Esg & Climate...

BMO Global Communication...

Nuveen ESG Dividend

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。